ASTRO 2025: 177Lu-PSMA Neoadjuvant to Ablative Radiotherapy for Oligorecurrent Prostate Cancer: Primary Endpoint Analysis of the Phase II LUNAR Randomized Trial – UroToday

Written by

admin

in

  1. ASTRO 2025: 177Lu-PSMA Neoadjuvant to Ablative Radiotherapy for Oligorecurrent Prostate Cancer: Primary Endpoint Analysis of the Phase II LUNAR Randomized Trial  UroToday
  2. Adding PSMA-targeting radioligand therapy to stereotactic body radiotherapy more than doubled progression-free survival in men with recurrent prostate cancer  UCLA Health
  3. ASTRO 2025: Conventional vs. Hypofractionated, Radiotherapy for High-Risk Prostate Cancer: 10-Year Outcomes of the Randomized, Non-Inferiority, Phase 3 PCS5 Trial  UroToday
  4. Radiopharmaceutical added to stereotactic radiation can delay prostate cancer progression  Medical Xpress
  5. ASTRO: Targeted Radioactive Therapy, New SBRT Approaches, 5DCT-Guided Imaging and More  Oncodaily

Continue Reading

More posts